Cowen Healthcare Royalty Partners Announces Name Change, Unveils New Website
STAMFORD, Conn., June 25, 2012 /PRNewswire/ -- Cowen Healthcare Royalty Partners, a global healthcare investment firm, today announced that it has changed its name to HealthCare Royalty Partners ("HC Royalty"). The intent is to differentiate the firm's principal investing business from Cowen and Company's financial advisory business. HC Royalty's existing relationship with Cowen Group, Inc. remains unchanged.
"We have built a strong reputation in this market and felt it was important to emphasize the essence of our brand with this name change. Our affiliation with Cowen remains the same and we look forward to their continued support," commented Todd C. Davis, Founding Managing Partner at HC Royalty. He continued, "Healthcare companies continue to look for innovative structured financing solutions to fund their corporate and development objectives. We believe we can offer them attractive solutions to achieve these goals and expect 2012 to be another record year for deal activity in the space."
In connection with the name change, HC Royalty has launched a new corporate website and relocated to new offices in Stamford, CT.
300 Atlantic Street, Suite 600
Stamford, CT 06901
HC Royalty has developed a broad and flexible investment platform that delivers innovative structured financing solutions for royalty owners and healthcare companies. The firm has raised $1.5 billion in new capital and executed 22 deals in 19 products, solidifying HC Royalty's leadership position in this market. Earlier this month, the firm completed an $18 million deal tied to Eligard®, a hormone compound for the treatment of advanced, hormone-dependent prostate cancer that is marketed by Astellas Pharma Europe Ltd. in Europe. HC Royalty also recently expanded its footprint in Stamford, CT with new additions to the investment, finance and legal teams and larger office space.
About HealthCare Royalty Partners
HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion of capital under management. The firm develops structured financing solutions for royalty owners and healthcare companies through the monetization of passive royalty streams, creation of Synthetic Royalty® financings and the purchase of debt and equity. For more information, visit www.healthcareroyalty.com.
Synthetic Royalty® is a registered trademark of HealthCare Royalty Management, LLC.
SOURCE HealthCare Royalty Partners
More by this Source
HealthCare Royalty Partners Appoints Pfizer Veteran to Strategic Advisory Board
Dec 04, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.